Page last updated: 2024-08-24

atorvastatin and Lupus Erythematosus, Systemic

atorvastatin has been researched along with Lupus Erythematosus, Systemic in 27 studies

Research

Studies (27)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's11 (40.74)29.6817
2010's11 (40.74)24.3611
2020's5 (18.52)2.80

Authors

AuthorsStudies
Li, J; Liu, X; Sun, Y; Yu, W; Yuan, L2
Cao, C; Sun, J; Tan, Y; Wu, H; Wu, Z; Xu, W; Yu, J; Zhu, M1
Arain, HA; Carsons, SE; DeLeon, J; Kasselman, LJ; Petri, M; Reiss, AB; Renna, HA; Voloshyna, I; Zhen, J1
Cestari, RN; de Oliveira, RDR; de Souza, FFL; Donadi, EA; Lanchote, VL; Nardotto, GHB; Pippa, LF; Rocha, A1
Barkoudah, E; Klein, JP; Mueller, AA; Tarter, LL; Vaidya, A1
Ardoin, SP; Barnhart, HX; Bowyer, SL; Brunner, HI; Eberhard, A; Evans, GW; Higgins, GC; Ilowite, NT; Imundo, LF; Jung, L; Kimura, Y; Klein-Gitelman, M; Levy, D; McCurdy, DK; Mieszkalski, KL; Punaro, L; Reed, AM; Sandborg, CI; Schanberg, LE; Sherry, DD; Silver, RM; Silverman, E; Singer, NG; Soep, JB; Thompson, SD; von Scheven, E; Wagner-Weiner, L; Wallace, C; Yow, E1
Farajzadegan, Z; Fatemi, A; Kazemi, M; Moosavi, M; Sayedbonakdar, Z; Smiley, A1
Castañeda, A; Castejon, R; Jimenez-Ortiz, C; Mellor-Pita, S; Sollet, A; Tutor-Ureta, P; Yebra-Bango, M1
Graham, KL; Higgins, JP; Ho, PP; Lee, LY; Steinman, L; Utz, PJ1
Ferringer, T; Lountzis, NI; Puri, PK; Tyler, W1
Ferreira, GA; Sato, EI; Teixeira, AL1
Christopher-Stine, L; Kiani, AN; Magder, LS; Petri, MA; Post, W1
Dziedzic, H; Gryga, K; Konieczynska, M; Musial, J; Plazak, W; Podolec, P; Tomkiewicz-Pajak, L1
Kiani, AN; Magder, LS; Petri, M; Post, WS1
Gabriel, CL; Kastelein, JJ; Major, AS; Mendez-Fernandez, YV; Stroes, ES; Tak, PP; van Leuven, SI; Wade, NS; Wilhelm, AJ1
Ravelli, A1
Ardoin, SP; Barnhart, HX; Bowyer, SL; Brunner, HI; Eberhard, A; Evans, GW; Higgins, GC; Ilowite, NT; Imundo, LF; Jung, L; Kimura, Y; Klein-Gitelman, M; McCurdy, D; Mieszkalski, KL; Provenzale, J; Punaro, M; Reed, AM; Sandborg, C; Schanberg, LE; Sherry, DD; Silver, R; Silverman, E; Singer, NG; Soep, JB; Thompson, SD; von Scheven, E; Wagner-Weiner, L; Wallace, C; Yow, E1
Erhart, KH; Graziadei, IW; Obermoser, GE; Sepp, NT; Vogel, W1
Abud-Mendoza, C; Baranda, L; Cruz-Rizo, J; Cuevas-Orta, E; de la Fuente, H; González-Amaro, R1
Belmont, HM; Lydon, E1
Cairns, T; Cook, HT; Elliot, V1
Ehrenstein, MR; Isenberg, DA; Jury, EC; Mauri, C1
Andrade, LE; Ferreira, GA; Navarro, TP; Sato, EI; Telles, RW1
Bielinska, A; Gluszko, P1
Kotyla, PJ1
Hidalgo, C; Jaimez, L; Jiménez-Alonso, J; Leon, L; Sabio, JM1

Reviews

1 review(s) available for atorvastatin and Lupus Erythematosus, Systemic

ArticleYear
[Statins--are they potentially useful in rheumatology?].
    Polskie Archiwum Medycyny Wewnetrznej, 2007, Volume: 117, Issue:9

    Topics: Arthritis, Rheumatoid; Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lupus Erythematosus, Systemic; Osteoporosis; Pyrroles; Rheumatic Diseases; Simvastatin; Treatment Outcome

2007

Trials

11 trial(s) available for atorvastatin and Lupus Erythematosus, Systemic

ArticleYear
Systemic Lupus Erythematosus Activity Affects the Sinusoidal Uptake Transporter OATP1B1 Evaluated by the Pharmacokinetics of Atorvastatin.
    Clinical and translational science, 2020, Volume: 13, Issue:6

    Topics: Adolescent; Adult; Area Under Curve; Atorvastatin; Case-Control Studies; Chemokine CCL2; Cytochrome P-450 CYP3A; Female; Healthy Volunteers; Humans; Interleukin-10; Liver-Specific Organic Anion Transporter 1; Lupus Erythematosus, Systemic; Male; Metabolic Clearance Rate; Midazolam; Middle Aged; Severity of Illness Index; Signal Transduction; Tumor Necrosis Factor-alpha; Young Adult

2020
Secondary analysis of APPLE study suggests atorvastatin may reduce atherosclerosis progression in pubertal lupus patients with higher C reactive protein.
    Annals of the rheumatic diseases, 2014, Volume: 73, Issue:3

    Topics: Adolescent; Age Factors; Atherosclerosis; Atorvastatin; Biomarkers; C-Reactive Protein; Carotid Arteries; Carotid Intima-Media Thickness; Cholesterol, LDL; Disease Progression; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lupus Erythematosus, Systemic; Male; Prospective Studies; Puberty; Pyrroles; Treatment Outcome

2014
Atorvastatin effect on systemic lupus erythematosus disease activity: a double-blind randomized clinical trial.
    Clinical rheumatology, 2014, Volume: 33, Issue:9

    Topics: Adult; Antirheumatic Agents; Atorvastatin; Blood Sedimentation; C-Reactive Protein; Double-Blind Method; Female; Heptanoic Acids; Humans; Lipids; Lupus Erythematosus, Systemic; Male; Middle Aged; Pyrroles; Severity of Illness Index; Treatment Outcome

2014
Atorvastatin therapy reduces interferon-regulated chemokine CXCL9 plasma levels in patients with systemic lupus erythematosus.
    Lupus, 2010, Volume: 19, Issue:8

    Topics: Adult; Atorvastatin; Chemokine CXCL9; Chemokines; Disease Progression; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interferons; Lupus Erythematosus, Systemic; Pyrroles; Severity of Illness Index

2010
Lupus Atherosclerosis Prevention Study (LAPS).
    Annals of the rheumatic diseases, 2011, Volume: 70, Issue:5

    Topics: Adolescent; Adult; Aged; Atherosclerosis; Atorvastatin; Carotid Artery Diseases; Coronary Artery Disease; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lupus Erythematosus, Systemic; Male; Middle Aged; Pyrroles; Severity of Illness Index; Tomography, X-Ray Computed; Treatment Outcome; Ultrasonography; Young Adult

2011
Influence of atorvastatin on coronary calcifications and myocardial perfusion defects in systemic lupus erythematosus patients: a prospective, randomized, double-masked, placebo-controlled study.
    Arthritis research & therapy, 2011, Jul-20, Volume: 13, Issue:4

    Topics: Adult; Aged; Atorvastatin; Calcinosis; Coronary Artery Disease; Coronary Vessels; Double-Blind Method; Female; Heart; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lupus Erythematosus, Systemic; Male; Middle Aged; Multimodal Imaging; Myocardial Perfusion Imaging; Myocardium; Positron-Emission Tomography; Prospective Studies; Pyrroles; Tomography, X-Ray Computed; Young Adult

2011
Predictors of progression in atherosclerosis over 2 years in systemic lupus erythematosus.
    Rheumatology (Oxford, England), 2011, Volume: 50, Issue:11

    Topics: Adult; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Calcium; Carotid Artery Diseases; Carotid Intima-Media Thickness; Comorbidity; Coronary Vessels; Disease Progression; Female; Heptanoic Acids; Humans; Lupus Erythematosus, Systemic; Male; Maryland; Pyrroles

2011
Use of atorvastatin in systemic lupus erythematosus in children and adolescents.
    Arthritis and rheumatism, 2012, Volume: 64, Issue:1

    Topics: Adolescent; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Carotid Intima-Media Thickness; Child; Disease Progression; Double-Blind Method; Female; Heptanoic Acids; Humans; Lipids; Lupus Erythematosus, Systemic; Male; Pyrroles; Treatment Outcome; Young Adult

2012
Therapy with statins in patients with refractory rheumatic diseases: a preliminary study.
    Lupus, 2003, Volume: 12, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Atorvastatin; Biomarkers; Blood Sedimentation; C-Reactive Protein; Child; Chloroquine; Dose-Response Relationship, Drug; Granulomatosis with Polyangiitis; Heptanoic Acids; HLA-DR Antigens; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Leukocytes, Mononuclear; Lupus Erythematosus, Systemic; Middle Aged; Proteinuria; Pyrroles; Rheumatic Diseases; Rheumatic Fever; Simvastatin; Treatment Outcome

2003
Avascular necrosis prevention with lipitor in lupus erythematosus.
    Lupus, 2005, Volume: 14, Issue:10

    Topics: Anticholesteremic Agents; Atorvastatin; Double-Blind Method; Heptanoic Acids; Humans; Lupus Erythematosus, Systemic; Osteonecrosis; Pyrroles

2005
Atorvastatin therapy improves endothelial-dependent vasodilation in patients with systemic lupus erythematosus: an 8 weeks controlled trial.
    Rheumatology (Oxford, England), 2007, Volume: 46, Issue:10

    Topics: Adult; Atorvastatin; Brachial Artery; Coronary Disease; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lupus Erythematosus, Systemic; Pyrroles; Risk Factors; Severity of Illness Index; Ultrasonography; Vasodilation

2007

Other Studies

15 other study(ies) available for atorvastatin and Lupus Erythematosus, Systemic

ArticleYear
Effects of atorvastatin and Zishen Qingqi granules on immune function and liver function of patients with systemic lupus erythematosus with mild and moderate activity.
    Pakistan journal of pharmaceutical sciences, 2021, Volume: 34, Issue:5(Special)

    Topics: Adult; Atorvastatin; Drug Therapy, Combination; Drugs, Chinese Herbal; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Lupus Erythematosus, Systemic; Male; Middle Aged; Retrospective Studies; Time Factors; Treatment Outcome; Young Adult

2021
Effects of atorvastatin and Zishen Qingqi granules on immune function and liver function of patients with systemic lupus erythematosus with mild and moderate activity.
    Pakistan journal of pharmaceutical sciences, 2022, Volume: 35, Issue:3(Special)

    Topics: Atorvastatin; Humans; Immunity; Liver; Lupus Erythematosus, Systemic; Retrospective Studies; Syndrome

2022
Immunomodulatory effects of atorvastatin on MRL/lpr mice.
    Advances in rheumatology (London, England), 2022, 12-05, Volume: 62, Issue:1

    Topics: Animals; Atorvastatin; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lupus Erythematosus, Systemic; Mice; Mice, Inbred MRL lpr

2022
Human Lupus Plasma Pro-Atherogenic Effects on Cultured Macrophages Are Not Mitigated by Statin Therapy: A Mechanistic LAPS Substudy.
    Medicina (Kaunas, Lithuania), 2019, Aug-21, Volume: 55, Issue:9

    Topics: Adult; Atherosclerosis; Atorvastatin; ATP Binding Cassette Transporter 1; ATP Binding Cassette Transporter, Subfamily G, Member 1; ATP-Binding Cassette Transporters; Cholesterol; Disease Progression; Female; Gene Expression; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Metabolism; Liver X Receptors; Lupus Erythematosus, Systemic; Macrophages; Male; Mixed Function Oxygenases; Plasma; PPAR gamma; RNA, Messenger

2019
Caught in a Flare.
    The New England journal of medicine, 2020, Aug-13, Volume: 383, Issue:7

    Topics: Arthralgia; Aspirin; Atorvastatin; Brain; Diagnosis, Differential; Exanthema; Fatigue; Female; Hematologic Tests; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lupus Erythematosus, Systemic; Magnetic Resonance Imaging; Nervous System Diseases; Platelet Aggregation Inhibitors; Secondary Prevention; Stroke; Young Adult

2020
Short-term atorvastatin therapy improves arterial stiffness of middle-aged systemic lupus erythematosus patients with pathological pulse wave velocity.
    Lupus, 2017, Volume: 26, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Drug Administration Schedule; Female; Humans; Lupus Erythematosus, Systemic; Middle Aged; Pulse Wave Analysis; Treatment Outcome; Vascular Stiffness; Young Adult

2017
Failure of oral atorvastatin to modulate a murine model of systemic lupus erythematosus.
    Arthritis and rheumatism, 2008, Volume: 58, Issue:7

    Topics: Administration, Oral; Animals; Antibodies, Antinuclear; Atorvastatin; Cell Proliferation; Cholesterol; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-4; Lupus Erythematosus, Systemic; Mice; Mice, Inbred NZB; Pyrroles; T-Lymphocytes; Treatment Outcome

2008
Hydroxychloroquine-induced hyperpigmentation: the staining pattern.
    Journal of cutaneous pathology, 2008, Volume: 35, Issue:12

    Topics: Aged; Antacids; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Aspirin; Atorvastatin; Calcium Carbonate; Cardiomyopathy, Restrictive; Citalopram; Connective Tissue Diseases; Diuretics; Female; Furosemide; Glucosamine; Heptanoic Acids; Humans; Hydroxychloroquine; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperpigmentation; Lupus Erythematosus, Systemic; Magnesium; Metolazone; Middle Aged; Naproxen; Omeprazole; Potassium Chloride; Prednisone; Pyrroles; Selective Serotonin Reuptake Inhibitors; Spironolactone

2008
Mycophenolate mofetil but not atorvastatin attenuates atherosclerosis in lupus-prone LDLr(-/-) mice.
    Annals of the rheumatic diseases, 2012, Volume: 71, Issue:3

    Topics: Animals; Atherosclerosis; Atorvastatin; CD4-Positive T-Lymphocytes; Cholesterol; Disease Models, Animal; Drug Evaluation, Preclinical; Drug Therapy, Combination; Female; Genetic Predisposition to Disease; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunity, Cellular; Immunosuppressive Agents; Lupus Erythematosus, Systemic; Mice; Mice, Inbred C57BL; Mycophenolic Acid; Pyrroles

2012
Should children and adolescents with systemic lupus erythematosus be given statin therapy to prevent early atherosclerosis?
    Arthritis and rheumatism, 2012, Volume: 64, Issue:1

    Topics: Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Female; Heptanoic Acids; Humans; Lupus Erythematosus, Systemic; Male; Pyrroles

2012
Drug-induced lupus-like syndrome associated with severe autoimmune hepatitis.
    Lupus, 2003, Volume: 12, Issue:5

    Topics: Anticholesteremic Agents; Atorvastatin; Female; Hepatitis, Autoimmune; Heptanoic Acids; Humans; Immunosuppressive Agents; Liver; Liver Failure; Lupus Erythematosus, Systemic; Middle Aged; Pyrroles

2003
Evolution of lesions over 10 years in a patient with SLE: flowchart approach to the new International Society of Nephrology (ISN)/Renal Pathology Society (RPS) classification of lupus nephritis.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 2006, Volume: 47, Issue:1

    Topics: Adolescent; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Atorvastatin; Biopsy, Needle; Disease Progression; Follow-Up Studies; Hematuria; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Immunoglobulin A; Immunoglobulin M; Immunosuppressive Agents; Kidney Glomerulus; Lupus Erythematosus, Systemic; Lupus Nephritis; Male; Organelles; Plasma Exchange; Pyrroles; Sclerosis; Severity of Illness Index; Software Design

2006
Atorvastatin restores Lck expression and lipid raft-associated signaling in T cells from patients with systemic lupus erythematosus.
    Journal of immunology (Baltimore, Md. : 1950), 2006, Nov-15, Volume: 177, Issue:10

    Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cells, Cultured; Enzyme Activation; Female; G(M1) Ganglioside; Heptanoic Acids; Humans; Intracellular Fluid; Kinetics; Lupus Erythematosus, Systemic; Lymphocyte Specific Protein Tyrosine Kinase p56(lck); Male; Membrane Microdomains; Middle Aged; Protein Prenylation; Pyrroles; Receptors, Antigen, T-Cell; Signal Transduction; T-Lymphocyte Subsets

2006
Comment on: Atorvastatin therapy improves endothelial-dependent vasodilation in patients with systemic lupus erythematosus: an 8 week controlled trial.
    Rheumatology (Oxford, England), 2008, Volume: 47, Issue:3

    Topics: Atorvastatin; Controlled Clinical Trials as Topic; Endothelium, Vascular; Female; Follow-Up Studies; Heptanoic Acids; Humans; Lupus Erythematosus, Systemic; Male; Pyrroles; Treatment Outcome; Vasodilation

2008
Atorvastatin-induced reversible positive antinuclear antibodies.
    The American journal of medicine, 2002, Volume: 112, Issue:4

    Topics: Adult; Antibodies, Antinuclear; Atorvastatin; Autoimmune Diseases; Heptanoic Acids; Histones; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lupus Erythematosus, Systemic; Male; Pyrroles

2002